The global Small Molecule API Market size is expected to reach USD 282.50 billion by 2030, expanding at
a CAGR of 5.44% during the forecast period, according to a new report by Grand
View Research, Inc. It is driven by an increase in demand for pharmaceuticals
globally and a high rate of new small molecule-based drug approval.
The increasing number of new pharmaceuticals entering
the market is creating a lucrative opportunity for key players. For instance,
as per NCBI in 2021, 75% of the drugs accepted by the FDA were small molecules,
with the dominant therapeutic area being oncology. Over 50% of these approvals
were from small and mid-sized companies which require support from CDMOs for
the commercialization of products that enhance the growth rate of CDMOs.
The COVID-19 pandemic has made supply-chain
shortcomings in the small-molecule API business apparent, as most of the production
facilities are located in Asian nations such as India and China. This has
increased the focus of players on creating an end-to-end integrated supply
chain for the clients and increased the number of facilities in western
countries with heightened support from the government for doing the same.
Merger and acquisition activities are frequently
being undertaken by the players to meet the soaring demands globally. For
instance, in April 2022, Novasep and PharmaZell announced a strategic merger
for the creation of a leading technologically-driven CDMO for complex small
molecules and specialty API production.
Expansion and diversification are becoming key
strategies used by key players in the market to maintain their market share.
For instance, in April 2021, Lonza announced its investment plan of USD 218.6
million for the construction of a manufacturing complex for small molecules in
Switzerland. The facility is expected to ensure continuity and flexibility of
supply for the products.
Emerging markets such as China, India, and Southeast
Asia represent significant opportunities for growth. Furthermore, niche areas
such as “halal API” further present growth opportunities owing to the rise in
the demand for drugs in the segment, majorly in Middle Eastern and Southeast
Asian nations. The synthetic small molecule API segment is largely driven by
the presence of small companies and CDMOs that cater to the changing
requirements of the industry.
List of Key Players in the Small Molecule API Market
- Merck & Co., Inc.
- AbbVie, Inc.
- Bristol-Myers Squibb Company
- Albemarle Corporation
- Boehringer Ingelheim International GmbH
- Cipla, Inc.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- Dr. Reddy’s Laboratories Ltd.
- Aurobindo Pharma
- Sun Pharmaceutical Industries Ltd.
Related Press Release@ Small Molecule API Market Report
Small Molecule API Market Report Highlights
- In 2021, synthetic APIs held the largest market share attributable
to the high demand for the production of pharmaceuticals that are required
in high volume
- The outsourced manufacturing segment held the largest market share
owing to a dependency of small and mid-sized companies on outsourcing for commercial
production
- Oncology is projected to grow at the fastest rate in the application
segment as the adoption of cancer treatments is rising, creating a strong
demand for API
- North America dominated the market in 2021 due to the presence of
key players and rising support from the government for enhancing the API
manufacturing capacity of the region
Small Molecule API Market Report Scope
|
Report Attribute |
Details |
|
Market size value in 2022 |
USD 186.08 billion |
|
Revenue forecast in 2030 |
USD 282.50 billion |
|
Growth rate |
CAGR of 5.44% from 2022 to 2030 |
|
Base year for estimation |
2021 |
|
Historical data |
2018 - 2020 |
|
Forecast period |
2022 - 2030 |
Related Reports@
High Potency API Contract Manufacturing Market
Synthetic Small Molecule API Market
Small Molecule API Market Segmentation
Grand View Research has segmented the global small
molecule API market based on type, manufacturer, application, and region:
Small Molecule API Type Outlook (Revenue, USD Billion,
2018 - 2030)
- Synthetic
- Biotech
Small Molecule API Manufacturer Outlook (Revenue, USD
Billion, 2018 - 2030)
- In-house
- Outsourced
Small Molecule API Application Outlook (Revenue, USD
Billion, 2018 - 2030)
- Cardiology
- Oncology
- CNS and Neurology
- Orthopedic
- Endocrinology
- Pulmonology
- Gastroenterology
- Nephrology
- Ophthalmology
- Others
Small Molecule API Regional Outlook (Revenue, USD
Billion, 2018 - 2030)
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
About Us:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
